Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 422 - 422

Published: Feb. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Language: Английский

---

Characterization of antimicrobial properties of TroH2A-29 peptide from golden pompano (Trachinotus ovatus)

Developmental & Comparative Immunology, Journal Year: 2025, Volume and Issue: 163, P. 105315 - 105315

Published: Jan. 11, 2025

Language: Английский

---

Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control—A Narrative Review

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Language: Английский

---

Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection

Antibiotics, Journal Year: 2025, Volume and Issue: 14(4), P. 400 - 400

Published: April 14, 2025

Background: All currently used therapeutic protocols and drugs for Clostridioides difficile infection (CDI) treatment do not have a satisfying success usually cost lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with + nifuroxazide as protocol medium–severe form CDI. In addition, effects standard on number stools stool consistency in CDI will be compared. Materials Methods: A prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group treated monotherapy. The other (vancomycin nifuroxazide). Results: demonstrated enhanced pharmacological management compared to Patients reported significantly lower first, second third control; first control (4.47 ± 2.20 5.70 1.91 (p = 0.024)), (2.37 0.85 3.13 0.90 0.001)), (1.53 0.51 1.80 0.61 0.035)). Also, controls noted significant improvements consistency, measured decrease completely watery 0.011 p < 0.001, respectively). Conclusions: Nifuroxazide accelerated improvement patient status hold promise novel regimen managing diagnosed

Language: Английский

---

Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach

Microorganisms, Journal Year: 2024, Volume and Issue: 12(11), P. 2256 - 2256

Published: Nov. 7, 2024

This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations microbial diversity composition can influence development, progression, treatment outcomes blood cancers. The mechanisms by which microbiota impacts these conditions are examined, including modulation of immune responses, production metabolites, effects intestinal barrier function. Recent advances microbiome-based therapies for treating preventing GvHD highlighted, with emphasis full ecosystem standardized donor-derived products. Overall, this underscores growing importance microbiome research hematology–oncology its potential to complement existing treatments improve thousands patients worldwide.

Language: Английский

---

Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection

Pathogens, Journal Year: 2024, Volume and Issue: 13(12), P. 1028 - 1028

Published: Nov. 21, 2024

Urinary tract infections (UTIs) are one of the most common bacterial infections, affecting more than 150 million people each year in world. UTIs have grown exponentially last few years. They represent a major load for both individuals and society. The highest incidence (about 55–60%) concerns women. Many pathogens involved UTIs, which derived from gut. Recent studies, together with recent diagnostic techniques (such as quantitative culture urine or next-generation sequencing), improved knowledge microbial communities urinary tract. It turned out that gut dysbiosis is strictly pathogenesis UTIs. In particular, human natural habitat Escherichia coli (E. coli), main bacterium responsible overgrowth E. pathogenic strains represents risk factor them. Furthermore, microbiota acts “global reservoir” genes conferring resistance to clinically relevant antibiotics, thus influencing treatment addition, differently past, idea sterile environment has been replaced by characterization microbiome. aim our review explore studies on association between microbiome summarize current about effects interactions considering “gut disease” not only disease providing new insight into therapeutic options such use probiotics.

Language: Английский

---

Identification of a novel antimicrobial peptide from amphioxus ribosomal protein L27

Fish & Shellfish Immunology, Journal Year: 2024, Volume and Issue: 157, P. 110063 - 110063

Published: Nov. 30, 2024

Language: Английский

---

Progress in the Treatment of Pediatric Antibiotic-Associated Diarrhea with Traditional Chinese Medicine and Western Medicine

Advances in Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(11), P. 1308 - 1317

Published: Jan. 1, 2024

Language: Английский

---